Please login to the form below

Not currently logged in

WHO recommends ‘life-saving’ IL-6 inhibitors for severe COVID-19

Roche's Actemra and Sanofi's Kevzara are included in WHO's updated patient care guidelines

The World Health Organization (WHO) has recommended IL-6 inhibitors from Sanofi and Roche as ‘life-saving’ drugs for the treatment of COVID-19 patients.

WHO’s updated patient care guidelines now include Roche’s Actemra (tocilizumab) and Sanofi’s Kevzara (sarilumab) for the treatment of patients who are severely or critically ill with COVID-19, particularly when administered alongside corticosteroids.

Both Actemra and Kevzara are IL-6 receptor agonists and are most commonly used to treat anti-inflammatory conditions, including arthritis.

IL-6 is thought to play a role in driving the overactive inflammatory response in the lungs of critically and severely ill COVID-19 patients.

The recommendations follow findings from a prospective and living network meta-analysis conducted by WHO, which also considered data from over 10,000 patients enrolled in 27 clinical trials.

According to WHO’s meta-analyses, when Kevzara or Actemra are administered to severely ill or critically ill COVID-19 patients, these drugs can reduce the risk of death by 13% when compared to standard care.

In addition, the risk of needing mechanical ventilation among these critically ill patients drops by 28% with IL-6 inhibitor treatment compared to standard care.

These findings translate to as many as 28 fewer deaths for every thousand critically ill patients, and 23 fewer patients out of a thousand requiring mechanical ventilation.

“These drugs offer hope for patients and families who are suffering from the devastating impact of severe and critical COVID-19. But IL-6 receptor blockers remain inaccessible and unaffordable for the majority of the world,” said Tedros Adhanom Ghebreyesus, director-general of WHO.

“The inequitable distribution of vaccines means that people in low- and middle-income countries are most susceptible to severe forms of COVID-19. So, the greatest need for these drugs is in countries that currently have the least access. We must urgently change this,” he added.

Earlier this year, a study led by Imperial College London also found that both Actemra and Kevzara cut the risk of death in critically ill COVID-19 patients.

Analysis from the REMAP-CAP trial found that both Actemra and Kevzara reduced mortality by 8.6%, and also improved recovery times among patients who are critically ill with COVID-19.

This reflects a reduction in the relative risk of death by 24% when given to patients within 24 hours of entering intensive care.

On average, patients treated with these drugs were able to leave the ICU around a week earlier than those not receiving these treatments.

Article by
Lucy Parsons

7th July 2021

From: Regulatory, Healthcare



COVID-19 Updates and Daily News

Featured jobs


Add my company
Medscape Education Global

Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide....

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...